Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent
AAN Position Statement
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 20, 2021
- Accepted in final form November 2, 2021
- First Published November 17, 2021.
Article Versions
- Previous version (November 17, 2021 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Winston Chiong, MD, PhD,
- Benjamin David Tolchin, MD, MS,
- Richard J. Bonnie, LLB,
- Katharina M. Busl, MD, MS,
- Salvador Cruz-Flores, MD,
- Leon G. Epstein, MD,
- Ericka P. Greene, MD,
- Judy Illes, CM, PhD,
- Matthew Kirschen, MD, PhD,
- Daniel G. Larriviere, MD, JD,
- Sneha Mantri, MD,
- Michael A. Rubin, MD,
- Barney J. Stern, MD,
- Lynne P. Taylor, MD;
- on behalf of the Ethics, Law, and Humanities Committee (a joint committee of the AAN, ANA, and CNS)
- Winston Chiong, MD, PhD,
NONE
NONE
(1) AAN Ethics, Law and Humanities Committee, travel and honoraria (2) NIH BRAIN Initiative NeuroEthics Working Group, travel and honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) UCSF Memory and Aging Center, clinical evaluation of patients with cognitive disorder, 10% effort
NONE
(1) NIH, R01MH126997, multi-principal investigator, 2021-2025 (1) NIH, R01AG058817, principal investigator, 2018-2023 (2) NIH, R01MH114860, multi-principal investigator, 2017-2021 (3) NIH, R01AG022983, principal investigator, 2017-2022 (4) NIH, R01AG056715, co-investigator, 2017-2022 (5) NIH, RF1AG029577, co-investigator, 2019-2024
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Benjamin David Tolchin, MD, MS,
NONE
NONE
1) American Academy of Neurology, travel funding 2) International League Against Epilepsy, travel funding 3) Columbia University Medical Center, travel funding
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Department of Veterans Affairs, Veterans Health Administration, VISN1 Career Development Award PI: Benjamin Tolchin, MD, MS Project period: 10/01/2018 Â 9/30/2020 2) Department of Veterans Affairs, Veterans Health Administration, Pain Research, Informatics, Multimorbidities, and Education (PRIME) Center, Locally Initiated Project 96-037 PI: Benjamin Tolchin, MD, MS Project period: 04/01/2018 Â 03/31/2019
NONE
C. G. Swebilius Trust: Swebilius Grant PI: Benjamin Tolchin, MD, MS Project period: 05/01/2018 Â 4/30/2020
NONE
NONE
NONE
NONE
NONE
NONE
- Richard J. Bonnie, LLB,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katharina M. Busl, MD, MS,
NONE
NONE
NONE
Neurocritical Care On Call, Editorial Board, Member, since 2017; Neurocritical Care On Call, Editor-in-Chief, since 2020 Critical Care Explorations, Associate Editor, since 2020
NONE
NONE
NONE
Guidepoint Techspert
NONE
Honorarium, Guest Editor for Continuum Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Salvador Cruz-Flores, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Galapagos Sunovion
NONE
NONE
NONE
NONE
Lone Star Stroke Consortium through the University of Texas System
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Leon G. Epstein, MD,
NONE
NONE
NONE
Associate Editor Annals of Clinical and Translational Neurology (ANA)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ericka P. Greene, MD,
Argenx Inc. ISIS FUS ALS
NONE
NONE
Journal Reviewer for Mitochondrion
NONE
Co-editor for Case files for Neurology McGraw Hill publication
NONE
NONE
Speaker for Alexion Pharmaceuticals, Inc on indications for Soliris in Myasthenia Gravis Contracted Speaker for Spinraza in ALS (have not spoken) Speaker for Hizentra in CIDP on behalf of Grifols, Inc
NONE
NONE
NONE
NONE
Endowed Chair support from philanthropic donations not related to publication
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Judy Illes, CM, PhD,
All my Board work is pro bono. I am the Vice Chair of the CIHR Standing Committee on Ethics and of the Internal Advisory Board of INMHA. I am also an elected member of the Research Leaders Forum of the Michael Smith Foundation for Health Research. I serve on a number of editorial boards with no compensation or conflict of interest (please see list below).
NONE
NONE
Canadian Journal of Bioethics, Editorial Board, current Journal of Law and the Biosciences, Editorial Board, current Frontiers - Ethics and Genetics, Editorial Board, on hold American Journal of Bioethics - Neuroscience, Senior Editorial Advisor
NONE
I receive ongoing royalties on the following books edited by me: Illes, J. (Ed.) Neuroethics: Defining the Issues in Theory, Practice and Policy, Oxford University Press, Oxford, UK, 2006.Illes, J., Sahakian, B.J. (Eds.) Handbook of Neuroethics, Oxford University Press, Oxford, UK, 2011. Carter, A., Hall, W., Illes, J. (Eds.) Addiction Neuroethics, Elsevier Press, San Diego, CA, 2012. Di Pietro, N.C. and Illes, J. (Eds.) The Use and Overuse of Antipsychotics in Children and Youth, Elsevier, San Diego, 2015. Illes, J. (Ed.) Neuroethics: Anticipating the Future, Oxford University Press, Oxford, UK, July 2017. Illes, J. (Ed.) Series: Developments in Neuroethics and Biomedicine, Elsevier Press, San Diego (2017-2023),Vol 1-4 vol. 5 and 6 in preparation).
NONE
NONE
NONE
NONE
NONE
NONE
NSERC NFRF Transformation grant Mend the Gap - A Transformative Biomaterials Platform for Spinal Cord Repair Sept 2021 Â Aug 2027 J. Madden (PI) J. llles and others (Co-PI) CIHR INMHA International Neuroethics Patent Initiative 1 February 2021 Â 30 January 2024 J. Illes (PI: Vancouver) T. Spranger (PI: Bonn) CIHR INMHA Canadian Brain Research Strategy Secretariat C June 2020 Â May 2025 Y. De Koninck and J. Illes (Co-PIs) CIHR and Canadian Cancer Society(Priority on Cannabis) Cannabis for Symptom Management in Children with Cancer: a Demonstration Project by the Canadian Childhood Cannabinoid Clinical Trials (C4T) Platform 1 April 2020 Â 30 May 2025 L. Kelly (PI) J. Illes (sub award PI @UBC) National Institutes of Health BRAIN Initiative on Neuroethics (RF1 # MH11780501) Informing Choice for Neurotechnological Innovation in Pediatric Epilepsy 1 September 2018 Â 31 August 2021 (extension through 2022) J. Illes (PI) $250,000 (CAD) 1 September 2018 Â 31 August 2021 (extension through 2022) J. Illes P.J. McDonald M. Connolly M. Harrison
CIHR INMHA in partnership with the European Fund for Neuro- science Research Psychiatric Neurosurgery  Ethical, Legal, and Societal Issues C $80,000 1 November 2015  31 October 2018 S. Muller, PI (Universitat-medizin Berlin, Germany) J. Illes (UBC Principal Investigator) University of Toronto (sub-contract) Pan-Canadian Neurotechnology Ethics Collaborative (PCNEC) NC $150,000 5 February 2018  4 February 2020
North Growth Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew Kirschen, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel G. Larriviere, MD, JD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sneha Mantri, MD,
NONE
NONE
NONE
(1) Journal of General Internal Medicine, Associate Editor of Healing Arts, 2020-2021
NONE
NONE
NONE
(1) Michael J Fox Foundation, (2) Deep Brain Innovations, LLC, (3) Grey Matter Technologies, LLC
NONE
NONE
NONE
(1) Cerevel Therapeutics; (2) Neuraly Rho
NONE
NONE
(1) The Michael J Fox Foundation for Parkinson's Research; (2) The Parkinson's Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Michael A. Rubin, MD,
NONE
NONE
NONE
Neurology Today, ethics editorial advisor, 2018-currently, unfunded
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barney J. Stern, MD,
1.I serve on the Scientific Advisory Board of the Foundation for Sarcoidosis Research.
NONE
NONE
As of July 1, 2017 I receive compensation from the AAN for my role as an Associate Editor of Neurology Today.
NONE
I have received royalties for contributing an article on Neurosarcoidosis to UpToDate.
NONE
NONE
NONE
NONE
NONE
NONE
I receive partial salary support from the NIH NINDS for my role as medical safety monitor for the CREST2 and SATURN clinical trials.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lynne P. Taylor, MD;
NONE
NONE
NONE
Neurology Now, Editorial Advisory Board, 2007-present
NONE
Navigating Life with a Brain Tumor, 2012, Neurology Now Books
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of the Ethics, Law, and Humanities Committee (a joint committee of the AAN, ANA, and CNS)
- From the Department of Neurology (W.C.), University of California San Francisco; Department of Neurology (B.D.T.), Yale School of Medicine, New Haven, CT; School of Law (R.J.B.), University of Virginia, Charlottesville; Departments of Neurology and Neurosurgery (K.M.B.), University of Florida, Gainesville; Department of Neurology (S.C.-F.), Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso; Departments of Neurology and Pediatrics (L.G.E.), Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Neurology (E.P.G.), Houston Methodist Hospital, TX; Neuroethics Canada and Division of Neurology (J.I.), University of British Columbia, Vancouver, Canada; Departments of Anesthesia & Critical Care, Pediatrics, and Neurology (M.K.), Children's Hospital of Philadelphia, Pennsylvania; Neuroscience Service Line, Inova Health System (D.G.L.), Falls Church, VA; Department of Neurology (S.M.), Duke University, Durham, NC; Departments of Neurology and Neurological Surgery (M.A.R.), University of Texas Southwestern Medical Center, Dallas; Department of Neurology (B.J.S.), Johns Hopkins University, Baltimore, MD; and Departments of Neurology and Neurosurgery (L.P.T.), University of Washington, Seattle.
- Correspondence
Dr. Chiong winston.chiong{at}ucsf.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Reader Response: Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement
- Robert E. Becker, Psychiatry, clinical pharmacology,, Aristeas Translational Medicine Corporation
Submitted November 23, 2021
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Podcast
Related Articles
- No related articles found.